WE AIM FOR AN ACTIVE LIFESTYLE AND IMPROVED QUALITY OF LIFE FOR THE MILLIONS AFFECTED BY CHRONIC INFLAMMATORY DISEASES

WE DEVELOP AN ANTI-INFLAMMATORY DRUG WITH FIRST-IN-CLASS POTENTIAL

We aim to eliminate or alleviate painful symptoms for millions of patients suffering from chronic inflammatory diseases. Lipum has a biological anti-inflammatory drug candidate developed against Rheumatoid Arthritis (RA) – an autoimmune disease characterized by chronic inflammation of the joints. It often causes disability and lowers the quality of life for millions.

Treatment of other chronic inflammatory conditions is also explored. Related diseases are such as Crohn’s disease, ulcerative colitis, ankylosing spondylitis, and psoriatic arthritis.

Our biological anti-inflammatory drug candidate provides a novel mechanism of action. Therefore, it is assumed to have less adverse effects than current treatments in use.

THE STORY BEHIND LIPUM

Lipum was originally founded based on a discovery made by sci­entists at Umeå University.

The history of the innovation goes back 25 years when Olle Hernell, Prof. of Pediatrics, and his group was studying the nutrition of breast milk in newborns during early infancy, focusing on a protein that is now known as bile salt-stimulated lipase (BSSL).

Redeye Life Science Day 2023

Watch Einar Pontén & New CEO Ola Sandborgh present at Redeye Life Science Day 2023 – 23 November.

PRESS RELEASES

Lipum announces that the first patient with rheumatoid arthritis (RA) has been enrolled and dosed with SOL-116 or placebo in the ongoing phase I clinical...
Lipum AB´s (publ) (“Lipum”) main owner Flerie Invest AB (“Flerie”) announced on 1 March 2024 that it has acquired an additional...
Lipum AB´s (publ) (“Lipum”) main owner Flerie Invest AB (“Flerie”) announced on 1 March 2024 that it has acquired an additional...